期刊文献+

甘精胰岛素联合口服降糖药对2型糖尿病患者血糖波动性的影响 被引量:9

Study on influence of Insulin Glargine with oral hypoglycemic agents on fluctuations of blood sugar in patients with type 2 diabetes
暂未订购
导出
摘要 目的研究甘精胰岛素联合口服降糖药对2型糖尿病患者血糖波动性的影响。方法以63例2型糖尿病患者为研究对象,将其分为甘精胰岛素联合口服阿卡波糖组(联合组,32例)和预混胰岛素组(预混组,31例),联合组每日给予皮下注射甘精胰岛素及餐前口服阿卡波糖,每日3次。预混组每日2次皮下注射门冬胰岛素。治疗2周后,监测并比较患者血糖变化,记录胰岛素使用情况。结果经过2周治疗后,联合组平均胰岛素使用量明显少于预混组,低血糖的发生率为40.63%,明显少于预混组(83.87%),两组比较差异有高度统计学意义(P<0.01)。治疗2周后两组平均血糖水平及高血糖曲线下面积(AUC)比较差异无统计学意义(P>0.05),而联合组标准差、每日平均血糖波动幅度及低血糖AUC明显低于预混组,两组比较差异有高度统计学意义(P<0.01)。结论口服降糖药对2型糖尿病控制不良时,联合应用甘精胰岛素能使血糖控制在较稳定水平,且血糖波动小,低血糖发生率相对较低。 Objective To study the influence of Insulin Glargine with oral hypoglycemic agents on volatility of blood sugar in patients with type 2 diabetes. Methods 63 patients with type 2 diabetes were divided into Insulin Glargine combined with oral Acarbose group (combined group, 32 cases) and premixed Insulin group (premixed group, 31 cases). Patients in the combined group were given Insulin Glargine, daily subcutaneous injection, and taking Acarbose, three times a day. Patients in the premixed group were given insulin aspart twice daily subcutaneous injection. Two weeks after the treatment, the changes of blood glucose were monitored and compared, the use of insulin was recorded. Results After 2 weeks of treatment, the mean insulin use was significantly less than the premixed group, the incidence of hypo- glycemia in the combined group (40.63%) was significantly less than the premixed group (83.87%), there was a statis- tically significant difference (P 〈 0.01). After two weeks of treatmenl, there were no significant differences about mean blood sugar levels and high blood glucose area under the curve (AUC) between two groups (P 〉 0.05), while standard deviation, the average daily blood sugar fluctuations and low glucose AUC in the combined group was significantly lower than the premixed group, there were statistically significant differences (P 〈 0.01). Conclusion When oral hypoglycemic agents control type 2 diabetes poorly, Insulin Glargine combined with oral hypoglycemic agents enables blood glucose control in a more stable level. Also it has small volatility in blood glucose and the relatively low incidence of hypoglycemia.
出处 《中国医药导报》 CAS 2013年第7期95-96,101,共3页 China Medical Herald
关键词 2型糖尿病 甘精胰岛素 预混胰岛素 血糖 波动 Type 2 diabetes Insulin Glargine Premixed Insulin Blood glucose Volatility
  • 相关文献

参考文献8

  • 1Giaccari A,Sorice G,Muscogiuri G. Glucose toxicity:the leading ac- tor in the pathogenesis and clinical history of type 2 diabetes-mecha- nisms and potentials for treatment [J]. Nutr Metab Cardiovasc Dis,2009,19(5):365-377.
  • 2Vazeou A. Continuous blood glucose monitoring in diabetes treatment [J]. Diabetes Res Clin Pract,2011,93(Suppl 1 ) : 125-130.
  • 3Van den Berghe G, Schetz M, Vlasselaers D. Clinical review :intensive insulin therapy in critically ill patients:NICE-SUGAR or Leuven blood glucose target [J]. J Clin Endocrinol Metab,2009,94(9):3163- 3170.
  • 4Watada H,Azuma K, Kawamor IR. Glucose fluctuation on the pro- gression of diabetic macroangiopathy-new findings from monocyte ad- hesion to endothelial cells [J]. Diabetes Res Clin Pract,2007,77(S1 ): 58-61.
  • 5Nalysnyk L,Hernandez-Medina M,Krishnarajah G. Glycaemic variabil-ity and complications in patients with diabetes mellitus :evidence from a systematic review of the literature [J]. Diabetes Obes Metab,2010,12 (4) :288-298.
  • 6Rosenstock J,Schwartz SL,Clark C,et al. Basal insulin therapy in type 2 diabetes:28-week comparison of insulin glargine (HOE 901 ) and NPH insulin [J]. Diabetes Care, 2001,24 ( 11 ) : 631-636.
  • 7Mattheu C ,Riddle MD. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients [J]. Diabetes Care,2003, 26 ( 11 ) : 3080-3086.
  • 8卜石,邢小燕,王娜,赵文惠,杨文英.长效胰岛素联合口服降糖药治疗2型糖尿病的疗效与安全性[J].中国循证医学杂志,2004,4(7):464-467. 被引量:157

二级参考文献8

  • 1Riddle MC,Rosenstock J,Gerich J.Insulin Glargine 4002 Study Investigators.The treat-to-target trial:randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients[J].Diabetes Care,2003; 26(11):3 080-3 086.
  • 2HOE 901/3002 Study Group.Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes[J].Diabetes Care,2000; 23(8):1 130-1 136
  • 3UKPDS Study Group.Stratton IM,Adler AI,Neil HAW,Matthews DR,Manley SE,Cull CA,Hadden D,Turner RC,Holman RR.Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes:prospective observational study (UKPDS 35) [J].BMJ,20
  • 4Wright A,Burden ACF,Paisey RB.Sulfonylurea Inadequacy:Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57)[J].Diabetes Care,2002; 25(2):330-336
  • 5Turner RC,Cull CA,Frighi V,Holman RR.Glycemic control with diet,sulfonylurea,metformin,or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies (UKPDS 49).UK Prospective Diabetes Study (UKPDS) Group[J].JAMA,1999;
  • 6UKPDS Study Group.Klein R,Klein BE,Moss SE.Relation of glycemic control to diabetic microvascular complications indiabetes mellitus[J].Ann Intern Med,1996;124(1 Pt 2):90-96
  • 7UKPDS Study Group.Overview of six years' therapy of type 2 diabetes-a progressive disease (UKPDS 16)[J].Diabetes Care,1995; 44(11):1 249-1 258
  • 8Matthaei S.Endocrine review[M],21(6):585-618

共引文献156

同被引文献58

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部